Omani business group Tawoos has announced that it has entered into an agreement with NMC Healthcare, a leading private healthcare provider group in UAE, to acquire NMC Oman. Founded in 2016, it comprises two hospitals and 6 clinics across the sultanate.
Mubadala Investment Company, an Abu Dhabi sovereign investor, today launched Mubadala Bio, a company committed to strengthening the life sciences sector in the UAE and advancing better health outcomes for the UAE and the world.
King Faisal Specialist Hospital and Research Centre (KFSHRC) has entered into an MoU with Cleveland Clinic to work together on clinical, operational, educational, and research initiatives involving autism and neurosciences.
The boards of directors of the European Investment Bank (EIB) and European Investment Fund (EIF) approved new operations totalling €9.1 billion to strengthen Europe’s security and defence, tech leadership and critical infrastructure.
Manufacturing engineers are at the forefront of bringing new medicines derived from human sources such as cells, blood and genes to patients, Mayo Clinic has said.
Saudi Arabia's Crown Prince His Royal Highness Prince Mohammed bin Salman bin Abdulaziz Al Saud today announced the launch of HUMAIN, a company that will operate and invest across the artificial intelligence (AI) value chain.
Aster DM Healthcare, one of the leading healthcare providers in the GCC, has announced that five of its hospitals have been recognised in Newsweek's prestigious World’s Best Hospitals 2025 list.
Ebn Sina Medical, a subsidiary of Aamal Company and a leading supplier of pharmaceutical, and Novo Nordisk, the Danish global healthcare company, have announced the availability of Wegovy (Semaglutide 2.4mg) in Qatar.
PureHealth Holding, a leading healthcare group in the Middle East, reported a revenue increase of 8% year-on-year to AED6.6 billion ($1.8 billion) driven by growth across all of PureHealth’s segments.
Novo Nordisk, a leading global healthcare company, has signed a deal with Lifera, a biopharma company owned by the Saudi sovereign wealth fund PIF, to pursue the localisation of the manufacturing of semaglutide GLP-1 treatments in the kingdom.
